Dossier
Chinese drug industry
Coverage of Chinese drug industry in the Nexus archive.
- From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
Biotechs are investing billions to develop a cure for alpha-1 antitrypsin deficiency (AATD), a rare liver disorder caused by a DNA mutation. The race involves U.S. and Chinese drug industries competing with dueling technologies, patent disputes, and a fractured alliance, highlighting intense global competition.